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Summary 
The College of American Pathologists offerd protocol to assist pathologists in providing cli-
nically useful and relevant information when reporting results of colon cancer surgical specimen 
examination. These recommendations are accepted by Croatian Society of Pathology and foren-
sic medicine, were published and recommended for evary-day pathologists work.  These proto-
cols are an educational tool to assist pathologists in the useful reporting of relevant information 
and applies to all primary carcinomas of the colon and rectum. Currently, the seventh edition 
TNM staging system for carcinoma of the colon and rectum of the American Joint Committee on 
Cancer (AJCC) and the International Union Against Cancer (UICC) is recommended.
Keywords: colon carcinoma; prognostic factors; predictive factors.
Surgical procedures for diagnosis colon carcinoma are: exscisional biopsy (pol-
ypectomy), local transanal resection, colectomy (total, partial or segmental) as well 
as rectal resection.  Pathologists should after correct grossing of specimens report 
several facts which have influence on staignig and prognosis of patients with colo-
rectal carcinoma such as: anatomic site, histological type (WHO), histological grade, 
TNM status, margins, lympho-vascular and perineural invasion, perforation, mi-
crosatellite instability, RAS status as well as treatment effect.   
Anatomic Sites
The protocol applies to all carcinomas arising in the colon and rectum. The co-
lon is divided in right, trasversal anl left colon. The right colon is subdivided into 
the cecum and the ascending colon. The left colon is subdivided into the descending 
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and sigmoid colon [1,2]. When measuring below with a rigid sigmoidoscope, rectum 
extends 16 cm from the anal verge. Tumors located at the border between 2 subsites 
of the colon (eg, cecum and ascending colon) are registered as tumors of the subsite 
that is more involved. If two subsites are involved to the same extent, the tumor is 
classified as an “overlapping” lesion. A tumor is classified as rectal if its inferior 
margin lies less than 16 cm from the anal verge or if any part of the tumor is located 
at least partly within the supply of the superior rectal artery. A tumor is classified as 
rectosigmoid when differentiation between rectum and sigmoid is not possible [3]. 
Histologic Types
For consistency in reporting, the histologic classification proposed by the World 
Health Organization (WHO) is recommended and follows [4]: 
• Adenocarcinoma
• Mucinous (colloid) adenocarcinoma (greater than 50% mucinous)
• Signet-ring cell carcinoma (greater than 50% signet-ring cells)
• Squamous cell carcinoma
• Adenosquamous carcinoma
• Medullary carcinoma
• Small cell carcinoma (high-grade neuroendocrine carcinoma)
• Undifferentiated carcinoma
• Other (specify)
By convention, signet-ring cell carcinomas, small cell carcinomas, and undiffe-
rentiated carcinomas are high grade. The only histologic types of colorectal carci-
noma that have been shown to have adverse prognostic significance independent 
of stage are signet-ring cell carcinoma and small cell carcinoma (high-grade neu-
roendocrine carcinoma), [5,6]. Medullary carcinoma is a distinctive histologic type 
strongly associated with high levels of microsatellite instability (MSI-H), indicative 
of defects in normal DNA repair gene function. Medullary carcinoma may occur eit-
her sporadically or in association with hereditary nonpolyposis colon cancer (HNP-
CC), [7,8]. This tumor type is characterized by solid growth in nested, organoid, 
or trabecular patterns, with no immunohistochemical evidence of neuroendocrine 
differentiation. Medullary carcinomas are also characterized by numerous tumor 
infiltrating lymphocytes. The term “carcinoma, NOS” (not otherwise specified) is 
not part of the WHO classification.
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Histologic Grade
A number of grading systems for colorectal cancer have been suggested, but a 
single widely accepted and uniformly used standard for grading is lacking. Most 
systems stratify tumors into 3 or 4 grades as grade 1 (well differntiated, grade 2 
(moderately differentiated, grade 3 (poorly diffrenetiated) and grade 4 (undifferen-
tiated). Despite a significant degree of interobserver variability, histologic grade has 
repeatedly been shown by multivariate analysis to be a stage-independent progno-
stic factor [9,10]. Specifically, it has been demonstrated that high tumor grade is an 
adverse prognostic factor. It is known that in most studies documenting the progno-
stic power of tumor grade, 2-tiered grade stratification were used as follows: a) low 
grade: well differentiated and moderately differentiated (histologicaly greater than 
or equal to 50% gland formation), b) high grade: poorly differentiated and undifferen-
tiated (less than 50% gland formation). Therefore, in light of its proven prognostic 
value, relative simplicity, and reproducibility, a 2-tiered grading system for colorec-
tal carcinoma (ie, low grade and high grade) is recommended.
Lympho-Vascular and Perineural Invasion
Venous invasion has been demonstrated by multivariate analysis to be an inde-
pendent adverse prognostic factor [11]. Invasion of extramural veins, in particular, 
has been shown to be an independent indicator of unfavorable outcome and increa-
sed risk of occurrence of hepatic metastasis. The significance of intramural venous 
invasion is less clear, because data specific to this issue are lacking. In several stu-
dies, both lymphatic invasion and perineural invasion have been shown by multi-
variate analysis to be independent indicators of poor prognosis and for that reason 
the presence or absence of tumor invasion of small, thin-walled vessels should be 
reported in all cases [12]. 
Perforation
Tumor perforation is an uncommon complication of colorectal cancer, but one 
that is associated with a poor outcome, including high in-hospital mortality and 
morbidity. Perforation of the uninvolved colon proximal to an obstructing tumor is 
also associated with high mortality because of generalized peritonitis and sepsis. 
Reported perforation rates range from 2.6% to 9%. Perforation is more likely to occur 
in older patients [13].
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Mesorectal margin
The quality of the surgical technique is a key factor in the success of surgical 
treatment for rectal cancer, both in the prevention of local recurrence and in long-
term survival. Numerous studies have demonstrated that total mesorectal excision 
(TME) improves local recurrence rates and the corresponding survival by as much 
as 20%. This surgical technique entails precise sharp dissection within the areo-
lar plane outside (lateral to) the visceral mesorectal fascia to remove the rectum. 
This plane encases the rectum, its mesentery, and all regional nodes and constitutes 
Waldeyer fascia. High-quality TME surgery reduces local recurrence from 20% to 
30%, to 8% to 10% or less, and increases 5-year survival from 48% to 68%. Adjuvant 
therapy in the presence of a high-quality TME may further reduce local recurrence 
(from 8% to 2.6%), [14].
Pathologic evaluation of the resection specimen has been shown to be a sensitive 
means of assessing the quality of rectal surgery. It is superior to indirect measures of 
surgical quality assessment, such as perioperative mortality, rates of complication, 
number of local recurrences, and 5-year survival. It has been shown that macrosco-
pic pathologic assessment of the completeness of the mesorectum of the specimen, 
scored as complete, partially complete, or incomplete, accurately predicts both local 
recurrence and distant metastasis. Microscopic parameters, such as the status of the 
circumferential resection margin, the distance between the tumor and nearest cir-
cumferential margin (ie. “surgical clearance”), and the distance between the tumor 
and the closest distal margin, are all important predictors of local recurrence and 
may be affected by surgical technique. There is strong evidence that the status of the 
circumferential resection margin is a powerful predictor of local recurrence but is 
inconsistently evaluated and underreported.
The nonperitonealized surface of the fresh specimen is examined circumferen-
tially, and the completeness of the mesorectum is scored as described as incomplete, 
nearly complete and complete. The entire specimen is scored according to the worst 
area. These stages are as follows: 
Incomplete 
• Little bulk to the mesorectum
• Defects in the mesorectum down to the muscularis propria
•  After transverse sectioning, the circumferential margin appears very irre-
gular
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Nearly Complete 
• Moderate bulk to the mesorectum
•  Irregularity of the mesorectal surface with defects greater than 5 mm, but 
none extending to the muscularis propria
•  No areas of visibility of the muscularis propria except at the insertion site of 
the levator ani muscles
Complete 
• Intact bulky mesorectum with a smooth surface
• Only minor irregularities of the mesorectal surface
• No surface defects greater than 5 mm in depth
• No coning toward the distal margin of the specimen
• After transverse sectioning, the circumferential margin appears smooth
Histopathologic Features Suggestive of MSI
Identification of MSI-H colorectal tumors is important, as mismatch repair defi-
ciency may serve as a prognostic marker of patient outcome, a predictive marker of 
response to chemotherapy, and as a screening tool for HNPCC (Lynch Syndrome). 
Revised Bethesda guidelines for HNPCC detection recommend testing colorectal 
tumors for MSI under the following circumstances [15]:
1. Colorectal cancer diagnosed in a patient who is younger than 50 years
2.  Presence of synchronous, metachronous, or other HNPCC-associated tu-
mors (endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, bi-
liary tract, small bowel, and brain tumors and sebaceous adenomas and 
keratoacanthomas), regardless of age
3.  Colorectal cancer with MSI-H histology† in a patient who is younger than 
60 years
4.  Colorectal cancer in 1 or more first-degree relatives with an HNPCC-related 
tumor, with 1 of the cancers being diagnosed in a person younger than 50 
years
5.  Colorectal cancer diagnosed in 2 or more first- or second-degree relatives 
with HNPCC-related tumors, regardless of age
MSI-H histologic features are defined as presence of tumor-infiltrating lympho-
cytes (only moderate- and high-density intratumoral lymphocytes (approximately 
3 or more per high-power field using hematoxylin-eosin–stained sections should 
be considered significant), Crohn-like lymphocytic reaction (lymphoid aggregated 
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or follicles are the tumor edge, not associated with preexisting lymph node), muci-
nous/signet-ring cell differentiation, or medullary growth pattern.[16] Other patho-
logic features associated with MSI-H status in colorectal carcinomas include right-
sided location, high-grade histology, and lack of dirty necrosis [17].
Margins
It may be helpful to mark the margin(s) closest to the tumor with ink following 
close examination of the serosal surface for puckering and other signs of tumor 
involvement. Margins marked by ink should be designated in the macroscopic des-
cription of the surgical pathology report. The serosal surface (visceral peritoneum) 
does not constitute a surgical margin. 
In addition to addressing the proximal and distal margins, the circumferential 
(radial) margin must be assessed for any segment either or incompletely encased 
by peritoneum. The circumferential (radial) margin represents the adventitial soft 
tissue margin closest to the deepest penetration of tumor and is created surgically 
by blunt or sharp dissection of the retroperitoneal or subperitoneal aspect, respec-
tively. Multivariate analysis has suggested that tumor involvement of the circum-
ferential (radial) margin is the most critical factor in predicting local recurrence in 
rectal cancer [18]. The circumferential (radial) margin is considered negative if the 
tumor is more than 1 mm from the inked nonperitonealized surface but should be 
recorded as positive if tumor is located 1 mm or less from the nonperitonealized 
surface because local recurrence rates are similar with clearances of 0 to 1 mm. 
The mesenteric resection margin is the only relevant circumferential margin in 
segments completely encased by peritoneum (eg, transverse colon). Involvement of 
this margin should be reported even if tumor does not penetrate the serosal surfa-
ce. Sections to evaluate the proximal and distal resection margins can be obtained 
either by longitudinal sections perpendicular to the margin or by en face sections 
parallel to the margin. The distance from the tumor edge to the closest resection 
margin(s) may also be important, particularly for low anterior resections. For the-
se cases, a distal resection margin of 2 cm is considered adequate; for T1 and T2 
tumors, 1 cm may be sufficient distal clearance. Anastomotic recurrences are rare 
when the distance to the closest transverse margin is 5 cm or greater. In cases of car-
cinoma arising in a background of inflammatory bowel disease, proximal and distal 
resection margins should be evaluated for dysplasia and active inflammation [19].
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Treatment Effect
Neoadjuvant chemoradiation therapy in rectal cancer is associated with signi-
ficant tumor response and downstaging [20]. Because eradication of the tumor, as 
detected by pathologic examination of the resected specimen, is associated with a 
significantly better prognosis, specimens from patients receiving neoadjuvant che-
moradiation should be thoroughly sectioned, with careful examination of the tumor 
site. Minimal residual disease has been shown to have a better prognosis than gross 
residual disease. Although several grading systems for tumor response have been 
advocated, a 3-point tumor regression grade has been shown to provide good inter-
observer reproducibility compared with 5-grade schemas, and to provide similar 
prognostic significance. Tumor regression should be assessed only in the primary 
tumor; lymph node metastases should not be included in the assessment. Acellular 
pools of mucin in specimens from patient receiving neoadjuvant therapy are consi-
dered to represent completely eradicated tumor and are not used to assign pT stage 
or counted as positive lymph nodes [21].
Tumor Deposits (Discontinuous Extramural Extension)
Irregular discrete tumor deposits in pericolic or perirectal fat away from the lea-
ding edge of the tumor and showing no evidence of residual lymph node tissue, but 
within the lymphatic drainage of the primary carcinoma, are considered peritumo-
ral deposits or satellite nodules and are not counted as lymph nodes replaced by tu-
mor. Most examples are due to lymphovascular or, more rarely, perineural invasion. 
Because these tumor deposits are associated with reduced disease-free and overall 
survival their number should be recorded in the surgical pathology report [22,23]. 
If tumor deposits are observed in lesions that would otherwise be classified as pT1 
(tumor confined to submucosa) or pT2 (tumor confined to muscularis propria), then 
the primary tumor classification is not changed, but the nodule is recorded in a se-
parate N category as N1c.
TNM and Anatomic Stage/Prognostic Groupings
Surgical resection remains the most effective therapy for colorectal carcinoma, 
and the best estimation of prognosis is derived from the pathologic findings on the 
resection specimen. The anatomic extent of disease is by far the most important 
prognostic factor in colorectal cancer. The protocol recommends the TNM staging 
system of the AJCC and the UICC but does not preclude the use of other staging 
systems.
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By AJCC/UICC convention, the designation “T” refers to a primary tumor that 
has not been previously treated. The symbol “p” refers to the pathologic classifi-
cation of the TNM, as opposed to the clinical classification, and is based on gross 
and microscopic examination. pT entails a resection of the primary tumor or biopsy 
adequate to evaluate the highest pT category, pN entails removal or biopsy of nodes 
adequate to validate lymph node metastasis, and pM implies microscopic examina-
tion of distant lesions. Clinical classification (cTNM) is usually carried out by the 
referring physician before treatment during initial evaluation of the patient or when 
pathologic classification is not possible [24].
TNM Descriptors 
T Category
For colorectal carcinomas, “carcinoma in situ” (pTis) as a staging term inclu-
des cancer cells confined within the glandular basement membrane (intraepithelial 
carcinoma, synonymous with high-grade dysplasia) or invasive into the mucosal 
lamina propria, up to but not through the muscularis mucosae (intramucosal car-
cinoma). Tumor extension through the muscularis mucosae into the submucosa is 
classified as T1. When tumor invides muscular layer is characterised as  T2, while 
infiltrating subserosa as T3. Direct invasion of other organs or structures includes 
invasion of other segments of colorectum by way of the serosa or mesocolon (eg, in-
vasion of the sigmoid colon by carcinoma of the cecum) is classified as pT4. In such 
a case, both an adjacent organ and the visceral peritoneum are penetrated by tumor. 
For rectal tumors, invasion of the external sphincter is classified as T3, whereas in-
vasion of the levator ani muscle(s) is classified as T4. Tumor in veins or lymphatics 
does not affect the pT classification. pT4 tumors can be divided in pT4a (serosal in-
volvement by tumor cells), and pT4b (direct invasion of adjacent organs). It has been 
demonstrated by multivariate analysis taht pT4a and pT4b tumors have a negative 
impact on prognosis [25]. 
N Category 
The accuracy and predictive value of stage II assignment are directly proporti-
onal to the thoroughness of the surgical technique in removing all regional nodes 
and the pathologic examination of the resection specimen in identifying and har-
vesting all regional lymph nodes for microscopic assessment. It has been suggested 
that 12 lymph nodes be considered the minimal acceptable harvest from a careful 
specimen dissection. Increasingly, however, evidence indicates that this bar should 
be raised, as the greater the number of nodes examined, the greater the likeliho-
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od that metastasis will be found, suggesting that no minimum number of nodes 
accurately or reliably stages all patients [26]. Routine assessment of regional lymph 
nodes is limited to conventional pathologic techniques (gross assessment and histo-
logic examination), and data are currently insufficient to recommend special me-
asures to detect micrometastasis or ITCs. Thus, neither multiple levels of paraffin 
blocks nor the use of special/ancillary techniques such as immunohistochemistry 
are recommended for routine examination of regional lymph nodes [24].
Regional lymph nodes. The number of lymph nodes recovered from resection 
specimen is dependent on several factors. Surgical technique, surgery volume, and 
patient factors (eg, age and anatomic variation) alter the actual number of nodes in a 
resection specimen, but the diligence and skill of the pathologist in identifying and 
harvesting lymph nodes in the resection specimen also are major factors. Lymph 
nodes may be more difficult to identify in specimens from patients who are obese 
or elderly, or after neoadjuvant therapy. Because it has been shown that nodal me-
tastasis in colorectal cancer is often found in small lymph nodes (<5 mm in diame-
ter), diligent search for lymph nodes is required on gross examination of resection 
specimens. If fewer than 12 lymph nodes are found, reexamining the specimen for 
additional lymph nodes, with or without visual enhancement techniques, should be 
considered [9]. The pathology report should clearly state the total number of lymph 
nodes examined and the total number involved by metastases [24].
Nonregional Lymph Nodes. For microscopic examination of lymph nodes in 
large resection specimens, lymph nodes must be designated as regional versus non-
regional, according to the anatomic location of the tumor. Metastasis to nonregional 
lymph nodes is classified as distant metastasis and designated as M1.
Lymph Nodes Replaced by Tumor. A tumor nodule in the pericolonic/perirectal fat 
without histologic evidence of residual lymph node tissue is classified as a tumor depo-
sit (peritumoral deposit or satellite nodule) and is not considered a positive lymph node. 
Such tumor deposits may represent discontinuous spread, lymph-vascular spread with 
extravascular extension, or totally replaced lymph nodes. In the absence of unequivocal 
lymph node metastases, tumor deposits are recorded as N1c [24].
Micrometastasis and Isolated Tumor Cells. A micrometastasis is defined as 
tumor measuring greater than 0.2 mm but less than or equal to 2.0 mm in greatest 
dimension. Micrometastases are classified as N1(mic) or M1(mic) in lymph nodes or 
at distant sites, respectively. Isolated tumor cells (ITCs) are defined as single tumor 
cells or small clusters of tumor cells measuring 0.2 mm or less, usually found by 
special techniques such as immunohistochemical staining, and are classified as N0. 
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Because the biologic significance of ITCs (either a single focus in a single node, mul-
tiple foci within a single node, or micrometastatic involvement of multiple nodes) 
remains unproven, N0 is considered justified. The number of lymph nodes involved 
by micrometastases or ITCs should be clearly stated.
TNM Anatomic Stage/Prognostic Groups 
Pathologic staging is usually performed after surgical resection of the primary 
tumor. Pathologic staging depends on pathologic documentation of the anatomic 
extent of disease, whether or not the primary tumor has been completely removed. 
If a biopsied tumor is not resected for any reason (eg, when technically unfeasible), 
and if the highest T and N categories or the M1 category of the tumor can be confir-
med microscopically, the criteria for pathologic classification and staging have been 
satisfied without total removal of the primary cancer [24].
TNM Stage Groupings 
Stage 0 Tis N0 M0*
Stage I T1 N0 M0
T2 N0 M0
Stage IIA T3 N0 M0
Stage IIB T4a N0 M0
Stage IIC T4b N0 M0
Stage IIIA T1–T2 N1 M0
T1 N2a M0
Stage IIIB T3–T4a N1 M0
T2–T3 N2a M0
T1–T2 N2b M0
Stage IIIC T4a N2a M0
T3–T4a N2b M0
T4b N1–N2 M0
Stage IVA Any T Any N M1a
Stage IVB Any T Any N M1b
Molecular Studies
Detection of defects in mismatch repair in colorectal carcinomas is important 
for detection of Lynch syndrome (a subset of HNPCC accounting for approximately 
2% of all colorectal carcinomas), and examination of the tissue for defective DNA 
mismatch repair is recommended if any of the criteria in the revised Bethesda gui-
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delines are met such as  primarily on at-risk populations, such as colorectal cancer 
patients younger than 50 years or patients with a strong family history of HNPCC-
associated tumors (eg, colorectal, endometrial, gastric, or upper urinary tract urot-
helial carcinoma). In addition, emerging data suggest that MSI-H in sporadic colon 
cancers is associated with better outcome and may serve as a predictor of response 
to 5-FU–based chemotherapy, although these latter indications for testing are not 
clearly established and have not been accepted as standard of care [27].
Patients with an MSI-H phenotype may have a germline mutation in one of se-
veral DNA mismatch repair (MMR) genes (eg, MLH1, MSH2, MSH6, or PMS2) and 
after appropriate genetic counseling may want to consider having such testing. Best 
method for testing is for that reason to use at least 5 microsatellite markers, generally 
mononucleotide or dinucleotide repeat markers (recomendation is to use a 5-marker 
panel consisting of 3 dinucleotide and 3 mononucleotide repeats for MSI testing. 
Many laboratories now use a commercially available kit for MSI testing that uses 
5 mono-nucleotide markers. The pathologists should help identify areas of the tu-
mor for DNA isolation that have at least this minimum content of tumors cells. MSI 
testing is frequently done in conjunction with immunohistochemical (IHC) testing 
for DNA MMR protein expression (ie, MLH1, MSH2, MSH6, PMS expression). If the 
results of DNA MMR IHC and MSI testing are discordant (eg, MSI-H phenotype 
with normal IHC or abnormal IHC with MSS phenotype), then the laboratory sho-
uld make sure that the same sample was used for MSI and IHC testing and that 
there was no sample mix-up. Ideally, the results of DNA MMR IHC and MSI testing 
should be incorporated into the surgical pathology report for the colorectal cancer 
case and an interpretation of the clinical significance of these findings provided. If 
DNA MMR IHC has not been performed, this testing should be recommended for 
any cases that show an MSI-H phenotype because this information will help iden-
tify the gene that is most likely to have a germ-line mutation (eg, a patient whose 
tumor shows loss of MSH2 and MSH6 expression, but retention of MLH1 and PMS2 
expression, is likely to have an MSH2 germline mutation).
Analysis for somatic mutations in the V600E hot spot in BRAF may be indicated 
for tumors that show MSI-H, as this mutation has been found in sporadic MSI-H 
tumors but not in HNPCC-associated cancers. Use of BRAF mutational analysis as a 
step before germline genetic testing in patients with MSI-H tumors may be a cost-ef-
fective means of identifying patients with sporadic tumors for whom further testing 
is not indicated [28].
The presence of the ras gene (KRAS and NRAS) mutation has been shown to 
be associated with lack of clinical response to therapies targeted at the epidermal 
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growth factor receptor (EGFR). While clinical guidelines for RAS mutational anal-
ysis are evolving, current provisional recommendations from the American Society 
for Clinical Oncology are that all patients with stage IV colorectal carcinoma who 
are candidates for anti-EGFR antibody therapy should have their tumor tested for 
KRAS and NRAS mutations [24,29].
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Sažetak
Protokol za patohistološki pregled kirurških uzoraka kolorektalnog karcinoma
Američka udruga patologa izradila je protokol preuzimanja uzoraka i pisanja izvješća za 
uzorke kolorektalnog karinoma koji će pružiti dovoljno relevantnih podataka za kliničku upo-
rabu. Ove preporuke su prihvaćene od strane Hrvatske udruge patologa i sudskih medicinara, 
te publicirane kao pomoć patolozima u svakodnevnom radu. Navedeni protokoli su edukativni 
i služe patolozima u pisanju patohistoloških izvješća koja sadržavaju relevantne informacije i 
primjenjuju se kod svih primarnih kolorektalnih karcinoma. Za procjenu stadija proširenosti ko-
lorektalnog karcinoma trenutačno se koristi sedmo izdanje TNM sustava koje je temeljeno na 
preporuci Američkog zajedničkog komiteta za rak (AJCC) i Internacionalne udruge protiv raka 
(UICC).
Ključne riječi: karcinom debelog crijeva; prognostički čimbenici; prediktivni čimbenici.
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